The role of BRAF/MEK inhibitors in resensitizingRAI-refractory thyroid cancer to iodine has also been promising, as selumetinib (aMEK inhibitor) (31) and dabrafenib(32) have been shown toincrease iodine uptake and retention in patients diagnosed with RAI-refractorythyroid cancer. Here, MAP2K7 is linked to thyroid gland carcinoma.